Published in Lancet on June 21, 1997
The role of needle exchange programs in HIV prevention. Public Health Rep (1998) 2.58
Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis (2010) 2.32
Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J (2006) 1.97
Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect (2006) 1.92
High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review. BMC Public Health (2013) 1.65
Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time. CMAJ (2000) 1.52
Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health (1999) 1.47
Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health (2001) 1.39
Structural interventions for HIV prevention in the United States. J Acquir Immune Defic Syndr (2010) 1.39
Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. Eur J Public Health (2010) 1.37
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
Exploring the impact of underage sex work among female sex workers in two Mexico-US border cities. AIDS Behav (2012) 1.32
HIV among injection drug users in large US metropolitan areas, 1998. J Urban Health (2005) 1.31
Drugscapes and the role of place and space in injection drug use-related HIV risk environments. Int J Drug Policy (2008) 1.29
Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health (2000) 1.22
Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health (2008) 1.18
Satellite exchange in the Baltimore Needle Exchange Program. Public Health Rep (1998) 1.17
Placing the dynamics of syringe exchange programs in the United States. Health Place (2006) 1.17
The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study. J Urban Health (2003) 1.16
HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health (2008) 1.14
NIMBY localism and national inequitable exclusion alliances: The case of syringe exchange programs in the United States. Geoforum (2007) 1.14
Secondary syringe exchange among injection drug users. J Urban Health (2003) 1.12
Six rapid assessments of alcohol and other substance use in populations displaced by conflict. Confl Health (2011) 1.11
Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health (2010) 1.03
Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy (2008) 1.02
Syringe availability as HIV prevention: a review of modalities. J Urban Health (2000) 1.02
Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. AIDS Res Hum Retroviruses (2009) 0.99
Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. J Urban Health (2008) 0.97
How far will they go? Assessing the travel distance of current and former drug users to access harm reduction services. Harm Reduct J (2015) 0.94
Hazardous alcohol consumption among young adult IDU and its association with high risk behaviors. Drug Alcohol Depend (2012) 0.92
Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug Alcohol Depend (2016) 0.91
Needle-exchange participation, effectiveness, and policy: syringe relay, gender, and the paradox of public health. J Urban Health (2001) 0.91
Needle exchange and the geography of survival in the South Bronx. Int J Drug Policy (2012) 0.91
Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduct J (2008) 0.90
Social network-related risk factors for bloodborne virus infections among injection drug users receiving syringes through secondary exchange. J Urban Health (2007) 0.90
Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users. Am J Epidemiol (2012) 0.89
HIV serodiscordant relationships in India: translating science to practice. Indian J Med Res (2011) 0.88
Harm reduction in hospitals: is it time? Harm Reduct J (2009) 0.88
Attitudes of North Carolina law enforcement officers toward syringe decriminalization. Drug Alcohol Depend (2014) 0.86
Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. J Epidemiol Community Health (2006) 0.85
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Optimal placement of syringe-exchange programs. J Urban Health (2004) 0.83
The role of epidemiology in needle exchange programs. Am J Public Health (2000) 0.83
Do metropolitan HIV epidemic histories and programs for people who inject drugs and men who have sex with men predict AIDS incidence and mortality among heterosexuals? Ann Epidemiol (2014) 0.82
Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine (2010) 0.82
Ability to access community-based needle-syringe programs and injecting behaviors among drug users: a cross-sectional study in Hunan Province, China. Harm Reduct J (2013) 0.80
Quantifying Syringe Exchange Program Operational Space in the District of Columbia. AIDS Behav (2016) 0.80
Harmful microinjecting practices among a cohort of injection drug users in vancouver Canada. Subst Use Misuse (2010) 0.80
Integrating health and prevention services in syringe access programs: a strategy to address unmet needs in a high-risk population. Public Health Rep (2014) 0.78
Assessing Syringe Exchange Program Access among Persons Who Inject Drugs (PWID) in the District of Columbia. J Urban Health (2016) 0.78
High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). BMC Public Health (2016) 0.78
Correlates of public support toward federal funding for harm reduction strategies. Subst Abuse Treat Prev Policy (2015) 0.77
Consequences of a restrictive syringe exchange policy on utilisation patterns of a syringe exchange program in Baltimore, Maryland: Implications for HIV risk. Drug Alcohol Rev (2015) 0.75
Factors associated with presence of pharmacies and pharmacies that sell syringes over-the-counter in Los Angeles County. J Urban Health (2013) 0.75
Client-identified needs and agency-provided services at a harm reduction community based organization in the District of Columbia. Harm Reduct J (2015) 0.75
Achieving NHAS 90/90/80 Objectives by 2020: An Interactive Tool Modeling Local HIV Prevalence Projections. PLoS One (2016) 0.75
Students as effective harm reductionists and needle exchange organizers. Subst Abuse Treat Prev Policy (2017) 0.75
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu. Retrovirology (2007) 0.75
HIV research in Australia: linking basic research findings with clinical and public health outcomes. Retrovirology (2006) 0.75
Assessing seasonality of travel distance to harm reduction service providers among persons who inject drugs. Harm Reduct J (2015) 0.75
Access to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative. Harm Reduct J (2017) 0.75
Legal space for syringe exchange programs in hot spots of injection drug use-related crime. Harm Reduct J (2016) 0.75
Impact Evaluation of a Policy Intervention for HIV Prevention in Washington, DC. AIDS Behav (2016) 0.75
Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc (2003) (2017) 0.75
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Changes in behavioural characteristics of elderly populations of local authority homes and long-stay hospital wards, 1976-7. Br Med J (1978) 3.06
Socioeconomic deprivation and notification rates for tuberculosis in London during 1982-91. BMJ (1995) 3.06
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64
HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16
Trends in infectious disease mortality in Australia, 1979-1994. Med J Aust (1998) 2.02
Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr (1999) 1.95
Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ (1997) 1.92
Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust (2000) 1.92
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78
Psychiatry services for elderly people. Doctors should be in the front line. BMJ (1993) 1.74
Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer (1988) 1.74
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
One hundred cases of suicide in elderly people. Br J Psychiatry (1995) 1.71
The prognosis of depression in old age. Br J Psychiatry (1986) 1.69
Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect (2006) 1.59
Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology (2000) 1.56
Perinatal exposure to HIV in Australia, 1982-1994. Med J Aust (1997) 1.54
Survival analyses of randomized clinical trials adjusted for patients who switch treatments. Stat Med (1996) 1.54
Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol (1997) 1.52
Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust (2000) 1.50
Linking prescription and patient-identifying data: a pilot study. Med J Aust (1992) 1.48
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46
Oral contraceptives and breast cancer: a national study. Br Med J (Clin Res Ed) (1986) 1.44
Recruitment activities and sociodemographic factors that predict attendance at a mammographic screening program. Am J Public Health (1994) 1.41
Detection of HCV RNA in semen. Lancet (2000) 1.41
Premature mortality in Australia 1983-1992, the first decade of the AIDS epidemic. Med J Aust (1995) 1.40
Use of interventions for reducing mother-to-child transmission of HIV in Australia. Med J Aust (2001) 1.40
Sexually transmissible diseases surveillance in Australia: towards a coordinated national system. Commun Dis Intell (1998) 1.40
Reporting of occupational exposures to blood-borne pathogens in Australian teaching hospitals. Med J Aust (1995) 1.38
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med (2007) 1.36
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee. Am J Public Health (1994) 1.32
Kaposi's sarcoma and protection from AIDS dementia complex. AIDS (1998) 1.30
Circumcision and male-to-male sexual transmission of HIV. AIDS (2001) 1.30
HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. Med J Aust (1997) 1.26
HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS (1998) 1.24
Predictors of recent HIV testing in homosexual men in Australia. HIV Med (2002) 1.23
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat (2007) 1.23
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
The benefits and risks of mammographic screening for breast cancer. Epidemiol Rev (1992) 1.23
HIV surveillance in hard-to-reach populations. AIDS (2001) 1.22
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
Self-report is a valid measure of circumcision status in homosexual men. Sex Transm Infect (2008) 1.18
Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer (1987) 1.15
Effectiveness, costs, and cost-effectiveness of recruitment strategies for a mammographic screening program to detect breast cancer. J Natl Cancer Inst (1992) 1.11
HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans R Soc Trop Med Hyg (1999) 1.09
Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.08
Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. HIV Med (2009) 1.08
Trends in Australian mortality of asthma, 1979-1985. Med J Aust (1989) 1.06
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect (2006) 1.04
The role of voluntary village aides in the control of malaria by presumptive treatment of fever. 2. Impact on village health. P N G Med J (1985) 1.02
HIV prevalence at reception into Australian prisons, 1991-1997. Med J Aust (1999) 1.01
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01
Secondary malignancies following cancer chemotherapy. Acta Oncol (1994) 0.99
Age-specific HIV incidence among homosexually active men in Australia. Med J Aust (1996) 0.98
A case-control study of diet and breast cancer in Argentina. Int J Cancer (1989) 0.98
Fertility and reproductive choice in women with HIV-1 infection. AIDS (1997) 0.95
Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis (1997) 0.94
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res Hum Retroviruses (1998) 0.94
The usage and costs of health services for HIV infection in Australia. AIDS (1995) 0.94
Epidemiology of HIV and AIDS in the Asia-Pacific region. Med J Aust (1996) 0.93
HIV infection in recipients of blood products from donors with known duration of infection. Lancet (1994) 0.92
Aplastic anemia, leukemia and other cancer mortality in a cohort of shoe workers exposed to benzene. Scand J Work Environ Health (1989) 0.92
Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med (2004) 0.92
Validation of linear cerebral atrophy markers in multiple sclerosis. J Clin Neurosci (2008) 0.91
Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med (2007) 0.91
Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings. HIV Med (2010) 0.91
An outbreak of a penicillin-sensitive strain of gonorrhoea in Sydney men. Genitourin Med (1994) 0.90
Prevalence of hepatitis C virus antibodies in Sydney blood donors. Med J Aust (1992) 0.90
Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sang (2001) 0.88
Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat (2003) 0.87
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS (2000) 0.86
Can data from HIV voluntary counselling and testing be used to assess the impact of public health interventions? A literature review. Int J STD AIDS (2009) 0.86
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS (1996) 0.86
Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med (2002) 0.86
Accuracy of clinical signs, SEP, and EEG in predicting outcome of hypoxic coma: a meta-analysis. Neurology (2010) 0.85
A comparison of patient interview data with pharmacy and medical records for patients with acquired immunodeficiency syndrome or human immunodeficiency virus infection. J Clin Epidemiol (1996) 0.83
HIV-1 infection among female commercial sex workers in rural Thailand. AIDS (1997) 0.83
Kaposi's sarcoma-associated herpesvirus: a sexually transmissible infection? J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.83
Where people die in Victoria. Med J Aust (1991) 0.82
HIV risk factors and seroprevalence in surgical patients. Med J Aust (1993) 0.82
Spectrum of AIDS-defining illnesses in Australia, 1992 to 1998: influence of country/region of birth. J Acquir Immune Defic Syndr (2001) 0.82
The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med (2007) 0.82
Antenatal HIV antibody testing in Australia. Med J Aust (1995) 0.81
Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee. AIDS (2000) 0.80
Risk of Kaposi's sarcoma and oroanal sexual contact. Am J Epidemiol (1997) 0.80
Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.80
Health Watch exposure estimates: do they underestimate benzene exposure? Chem Biol Interact (2005) 0.79
The role of voluntary village aides in the control of malaria by presumptive treatment of fever. 1. Selection, training and practice. P N G Med J (1985) 0.79
HIV and AIDS in aboriginal and Torres Strait Islander Australians: 1992-1998. The National HIV Surveillance Committee. Med J Aust (2000) 0.79